Prion-like features of misfolded Aβ and tau aggregates

Virus Research

Volumn 207, Issue , 2015, Pages 106-112

  Morales, Rodrigo ^a   Callegari, Keri ^a   Soto, Claudio ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Amyloid ; Prion; Prion like mechanisms; Tau

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN; PRION;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BLOOD BRAIN BARRIER; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; CORTICOBASAL DEGENERATION; HUMAN; NONHUMAN; PICK PRESENILE DEMENTIA; PRION; PRION DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; PROTEIN UNFOLDING; RETROGRADE NERVE FIBER TRANSPORT; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCY;

ANIMALIA;

AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; PRIONS; PROTEIN AGGREGATES; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; TAU PROTEINS;

EID: 84938743829     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.12.031     Document Type: Article

References (90)

1. Aguzzi A., Heikenwalder M., Polymenidou M. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 2007, 8:552-561.
2. Alper T. Scrapie agent unlike viruses in size and susceptibility to inactivation by ionizing or ultraviolet radiation. Nature 1985, 317:750.
3. Atarashi R., Satoh K., Sano K., Fuse T., Yamaguchi N., Ishibashi D., Matsubara T., Nakagaki T., Yamanaka H., Shirabe S., Yamada M., Mizusawa H., Kitamoto T., Klug G., McGlade A., Collins S.J., Nishida N. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 2011, 17:175-178.
4. Baker H.F., Ridley R.M., Duchen L.W., Crow T.J., Bruton C.J. Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int. J. Exp. Pathol. 1993, 74:441-454.
5. Baker H.F., Ridley R.M., Duchen L.W., Crow T.J., Bruton C.J. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol. Neurobiol. 1994, 8:25-39.
6. Bartz J.C., Aiken J.M., Bessen R.A. Delay in onset of prion disease for the HY strain of transmissible mink encephalopathy as a result of prior peripheral inoculation with the replication-deficient DY strain. J. Gen. Virol. 2004, 85:265-273.
7. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
8. Bueler H., Aguzzi A., Sailer A., Greiner R.A., Autenried P., Aguet M., Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993, 73:1339-1347.
9. Castilla J., Saa P., Soto C. Detection of prions in blood. Nat. Med. 2005, 11:982-985.
10. Clavaguera F., Akatsu H., Fraser G., Crowther R.A., Frank S., Hench J., Probst A., Winkler D.T., Reichwald J., Staufenbiel M., Ghetti B., Goedert M., Tolnay M. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9535-9540.
11. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
12. Clavaguera F., Hench J., Lavenir I., Schweighauser G., Frank S., Goedert M., Tolnay M. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014, 127:299-301.
13. Clinton L.K., Blurton-Jones M., Myczek K., Trojanowski J.Q., LaFerla F.M. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 2010, 30:7281-7289.
14. Collinge J., Clarke A.R. A general model of prion strains and their pathogenicity. Science 2007, 318:930-936.
15. Dawkins E., Small D.H. Insights into the physiological function of the beta-amyloid precursor protein: beyond Alzheimer's disease. J. Neurochem. 2014, 129:756-769.
16. de Calignon C.A., Polydoro M., Suarez-Calvet M., William C., Adamowicz D.H., Kopeikina K.J., Pitstick R., Sahara N., Ashe K.H., Carlson G.A., Spires-Jones T.L., Hyman B.T. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
17. Diaz-Espinoza R., Soto C. Generation of prions in vitro and the protein-only hypothesis. Prion 2010, 4:53-59.
18. Domert J., Rao S.B., Agholme L., Brorsson A.C., Marcusson J., Hallbeck M., Nath S. Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol. Dis. 2014, 65:82-92.
19. Duran-Aniotz C., Morales R., Moreno-Gonzalez I., Hu P.P., Fedynyshyn J., Soto C. Aggregate-depleted brain fails to induce Abeta deposition in a mouse model of Alzheimer's disease. PLoS One 2014, 9:e89014.
20. Eisele Y.S., Bolmont T., Heikenwalder M., Langer F., Jacobson L.H., Yan Z.X., Roth K., Aguzzi A., Staufenbiel M., Walker L.C., Jucker M. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12926-12931.
21. Eisele Y.S., Obermuller U., Heilbronner G., Baumann F., Kaeser S.A., Wolburg H., Walker L.C., Staufenbiel M., Heikenwalder M., Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010, 330:980-982.
22. Fritschi S.K., Cintron A., Ye L., Mahler J., Buhler A., Baumann F., Neumann M., Nilsson K.P., Hammarstrom P., Walker L.C., Jucker M. Abeta seeds resist inactivation by formaldehyde. Acta Neuropathol. 2014, 128:477-484.
23. Frost B., Jacks R.L., Diamond M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284:12845-12852.
24. Giacobini E., Gold G. Alzheimer disease therapy - moving from amyloid-beta to tau. Nat. Rev. Neurol. 2013, 9:677-686.
25. Gibbs C.J., Gajdusek C.D., Asher D.M., Alpers M.P., Beck E., Daniel P.M., Matthews W.B. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 1968, 161:388-389.
26. Gibbs C.J., Gajdusek D.C., Latarjet R. Unusual resistance to ionizing radiation of the viruses of kuru, Creutzfeldt-Jakob disease, and scrapie. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:6268-6270.
27. Goedert M., Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990, 9:4225-4230.
28. Gotz J., Chen F., Van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
29. Goudsmit J., Morrow C.H., Asher D.M., Yanagihara R.T., Masters C.L., Gibbs C.J., Gajdusek D.C. Evidence for and against the transmissibility of Alzheimer disease. Neurology 1980, 30:945-950.
30. Griffith J.S. Self-replication and scrapie. Nature 1967, 215:1043-1044.
31. Haass C., Hung A.Y., Schlossmacher M.G., Oltersdorf T., Teplow D.B., Selkoe D.J. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. N. Y. Acad. Sci. 1993, 695:109-116.
32. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
33. Harper J.D., Lansbury P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66:385-407.
34. Heilbronner G., Eisele Y.S., Langer F., Kaeser S.A., Novotny R., Nagarathinam A., Aslund A., Hammarstrom P., Nilsson K.P., Jucker M. Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice. EMBO Rep. 2013, 14:1017-1022.
35. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
36. Iba M., Guo J.L., McBride J.D., Zhang B., Trojanowski J.Q., Lee V.M. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 2013, 33:1024-1037.
37. Irwin D.J., Abrams J.Y., Schonberger L.B., Leschek E.W., Mills J.L., Lee V.M., Trojanowski J.Q. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 2013, 70:462-468.
38. Jarrett J.T., Lansbury P.T. Seeding one-dimensional crystallization of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993, 73:1055-1058.
39. Jones E.M., Surewicz W.K. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell 2005, 121:63-72.
40. Kane M.D., Lipinski W.J., Callahan M.J., Bian F., Durham R.A., Schwarz R.D., Roher A.E., Walker L.C. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J. Neurosci. 2000, 20:3606-3611.
41. Kelly J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 1996, 6:11-17.
42. Kimberlin R.H., Walker C.A. Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly. J. Gen. Virol. 1986, 67(Pt 2):255-263.
43. Knowles T.P., Vendruscolo M., Dobson C.M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014, 15:384-396.
44. Lacroux C., Comoy E., Moudjou M., Perret-Liaudet A., Lugan S., Litaise C., Simmons H., Jas-Duval C., Lantier I., Beringue V., Groschup M., Fichet G., Costes P., Streichenberger N., Lantier F., Deslys J.P., Vilette D., Andreoletti O. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog. 2014, 10:e1004202.
45. Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Guerrero-Munoz M.J., Kiritoshi T., Neugebauer V., Jackson G.R., Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2012, 2:700.
46. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
47. Legname G., Baskakov I.V., Nguyen H.O., Riesner D., Cohen F.E., DeArmond S.J., Prusiner S.B. Synthetic mammalian prions. Science 2004, 305:673-676.
48. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
49. Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012, 7:e31302.
50. Mahal S.P., Baker C.A., Demczyk C.A., Smith E.W., Julius C., Weissmann C. Prion strain discrimination in cell culture: the cell panel assay. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20908-20913.
51. Manuelidis E.E., de Figueiredo J.M., Kim J.H., Fritch W.W., Manuelidis L. Transmission studies from blood of Alzheimer disease patients and healthy relatives. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:4898-4901.
52. Meyer V., Dinkel P.D., Rickman H.E., Margittai M. Amplification of Tau fibrils from minute quantities of seeds. Biochemistry 2014, 53:5804-5809.
53. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.L., Vigouret J.M., Paganetti P., Walsh D.M., Mathews P.M., Ghiso J., Staufenbiel M., Walker L.C., Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
54. Moda F., Gambetti P., Notari S., Concha-Marambio L., Catania M., Park K.W., Maderna E., Suardi S., Haik S., Brandel J.P., Ironside J., Knight R., Tagliavini F., Soto C. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N. Engl. J. Med. 2014, 371:530-539.
55. Morales R., Abid K., Soto C. The prion strain phenomenon: molecular basis and unprecedented features. Biochim. Biophys. Acta 2007, 1772:681-691.
56. Morales R., Duran-Aniotz C., Castilla J., Estrada L.D., Soto C. De novo induction of amyloid-beta deposition in vivo. Mol. Psychiatry 2012, 17:1347-1353.
57. Morales R., Duran-Aniotz C., Diaz-Espinoza R., Camacho M.V., Soto C. Protein misfolding cyclic amplification of infectious prions. Nat. Protoc. 2012, 7:1397-1409.
58. Morales R., Estrada L.D., Diaz-Espinoza R., Morales-Scheihing D., Jara M.C., Castilla J., Soto C. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J. Neurosci. 2010, 30:4528-4535.
59. Morales R., Moreno-Gonzalez I., Soto C. Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013, 9:e1003537.
60. Moreno-Gonzalez I., Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin. Cell Dev. Biol. 2011, 22:482-487.
61. Olichney J.M., Galasko D., Salmon D.P., Hofstetter C.R., Hansen L.A., Katzman R., Thal L.J. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998, 51:351-357.
62. Orru C.D., Wilham J.M., Vascellari S., Hughson A.G., Caughey B. New generation QuIC assays for prion seeding activity. Prion 2012, 6:147-152.
63. Petkova A.T., Leapman R.D., Guo Z., Yau W.M., Mattson M.P., Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 2005, 307:262-265.
64. Probst A., Gotz J., Wiederhold K.H., Tolnay M., Mistl C., Jaton A.L., Hong M., Ishihara T., Lee V.M., Trojanowski J.Q., Jakes R., Crowther R.A., Spillantini M.G., Burki K., Goedert M. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. 2000, 99:469-481.
65. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144.
66. Prusiner S.B. Some speculations about prions, amyloid, and Alzheimer's disease. N. Engl. J. Med. 1984, 310:661-663.
67. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13363-13383.
68. Ridley R.M., Baker H.F., Windle C.P., Cummings R.M. Very long term studies of the seeding of beta-amyloidosis in primates. J. Neural Transm. 2006, 113:1243-1251.
69. Rosen R.F., Fritz J.J., Dooyema J., Cintron A.F., Hamaguchi T., Lah J.J., LeVine H., Jucker M., Walker L.C. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J. Neurochem. 2012, 120:660-666.
70. Saa P., Castilla J., Soto C. Presymptomatic detection of prions in blood. Science 2006, 313:92-94.
71. Saborio G.P., Permanne B., Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411:810-813.
72. Salvadores N., Shahnawaz M., Scarpini E., Tagliavini F., Soto C. Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer's disease. Cell Rep. 2014, 7:261-268.
73. Sanders D.W., Kaufman S.K., DeVos S.L., Sharma A.M., Mirbaha H., Li A., Barker S.J., Foley A.C., Thorpe J.R., Serpell L.C., Miller T.M., Grinberg L.T., Seeley W.W., Diamond M.I. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82:1271-1288.
74. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
75. Sipe J.D., Cohen A.S. Review: history of the amyloid fibril. J. Struct. Biol. 2000, 130:88-98.
76. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 2001, 498:204-207.
77. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:49-60.
78. Soto C. Prion hypothesis: the end of the controversy?. Trends Biochem. Sci. 2011, 36:151-158.
79. Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012, 149:968-977.
80. Soto C., Castilla J. The controversial protein-only hypothesis of prion propagation. Nat. Med. 2004, 10:S63-S67.
81. Soto C., Estrada L., Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem. Sci. 2006, 31:150-155.
82. Soto C., Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol. Med. 2011, 17:14-24.
83. Spillantini M.G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998, 21:428-433.
84. Stohr J., Condello C., Watts J.C., Bloch L., Oehler A., Nick M., DeArmond S.J., Giles K., DeGrado W.F., Prusiner S.B. Distinct synthetic Abeta prion strains producing different amyloid deposits in bigenic mice. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10329-10334.
85. Stohr J., Watts J.C., Mensinger Z.L., Oehler A., Grillo S.K., DeArmond S.J., Prusiner S.B., Giles K. Purified and synthetic Alzheimer's amyloid beta (Abeta) prions. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:11025-11030.
86. Tsigelny I.F., Crews L., Desplats P., Shaked G.M., Sharikov Y., Mizuno H., Spencer B., Rockenstein E., Trejo M., Platoshyn O., Yuan J.X., Masliah E. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 2008, 3:e3135.
87. Wang F., Wang X., Yuan C.-G., Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010, 327:1132-1135.
88. Watts J.C., Condello C., Stohr J., Oehler A., Lee J., DeArmond S.J., Lannfelt L., Ingelsson M., Giles K., Prusiner S.B. Serial propagation of distinct strains of Abeta prions from Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10323-10328.
89. Weissmann C., Raeber A.J., Montrasio F., Hegyi I., Frigg R., Klein M.A., Aguzzi A. Prions and the lymphoreticular system. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356:177-184.
90. Will R.G. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br. Med. Bull. 2003, 66:255-265.